Immunome, Inc.
IMNM
$19.37
$2.2813.34%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | 4.02M | 2.93M | 2.74M | 2.91M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | 4.02M | 2.93M | 2.74M | 2.91M |
| Cost of Revenue | 49.19M | 40.45M | 36.87M | 47.89M | 37.20M |
| Gross Profit | -49.19M | -36.44M | -33.95M | -45.15M | -34.29M |
| SG&A Expenses | 10.95M | 10.04M | 10.69M | 10.45M | 9.53M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 60.14M | 50.49M | 47.56M | 58.34M | 46.73M |
| Operating Income | -60.14M | -46.48M | -44.64M | -55.60M | -43.82M |
| Income Before Tax | -57.46M | -43.40M | -41.64M | -80.25M | -47.10M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -57.46M | -43.40M | -41.64M | -80.25M | -47.10M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -57.46M | -43.40M | -41.64M | -80.25M | -47.10M |
| EBIT | -60.14M | -46.48M | -44.64M | -55.60M | -43.82M |
| EBITDA | -59.55M | -45.84M | -44.03M | -55.15M | -43.41M |
| EPS Basic | -0.65 | -0.50 | -0.52 | -1.28 | -0.78 |
| Normalized Basic EPS | -0.41 | -0.31 | -0.33 | -0.53 | -0.42 |
| EPS Diluted | -0.65 | -0.50 | -0.52 | -1.28 | -0.78 |
| Normalized Diluted EPS | -0.41 | -0.31 | -0.33 | -0.53 | -0.42 |
| Average Basic Shares Outstanding | 87.96M | 87.01M | 79.41M | 62.84M | 60.21M |
| Average Diluted Shares Outstanding | 87.96M | 87.01M | 79.41M | 62.84M | 60.21M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |